Torsade de pointes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]
Overview
Torsade de pointes, in French means “Twisting of the Points”. It is characterized by a polymorphic ventricular tachycardia and can occur in the congenital long QT syndromes, electrolyte abnormalities (hypomagnesemia, hypokalemia), usage of certain drugs like antiarrhythmic (quinidine), nonsedating antihistamines (terfenadine); antibiotics (erythromycin) and neuroleptics (thioridazine).
Historical Perspective
The term “torsade de pointes” was first described by Dessertenne in 1966, based on the characteristic “twisting” pattern of ventricular tachycardia seen on EKG.
Pathophysiology
Torsades de pointes is defined as the presence of polymorphic ventricular tachycardia with a prolonged QT segment on EKG. It is characterized by a constantly changing rhythm amplitude which comes from the ventricular depolarizing waves constantly shifting its axis. The underlying mechanism is thought to be triggered activity arising as a consequence of early after-depolarizations. During Torsade de pointes the ventricles depolarize in a circular fashion resulting in QRS complexes with a continuously turning heart axis around the baseline (hence the name Torsade de Pointes).
Causes
Common causes for torsades de pointes include hypomagnesemia and hypokalemia. It is commonly seen in malnourished individuals and chronic alcoholics. Drug interactions such as erythromycin or Avelox, taken concomitantly with inhibitors like nitroimidazole, diarrhea, dietary supplements, and various medications like methadone, lithium, tricyclic antidepressants or phenothiazines may also contribute to causing torsades de pointes.
Differentiating Torsades de pointes from other Conditions
Torsades de pointes should be differentiated from other conditions or disorders that may present in a similar way, such as other arrhythmias, drug toxicity, syncope and other cardiac conditions.
Risk Factors
Long QT syndrome is a risk factor for developing torsades de pointes, and can either be inherited as congenital mutations of ion channels carrying the cardiac impulse/action potential, or acquired as a result of drugs that block these cardiac ion currents. Other risk factors include electrolyte abnormalities, heart failure, left ventricular hypertrophy, female gender or renal and liver failure. Being on certain medications also pose a risk for developing torsades de pointes.
Natural History, Complications and Prognosis
Although Torsades de Pointes (TdP) is a rare ventricular arrhythmia, it can degenerate into ventricular fibrillation, leading to death without rapid medical intervention.
Diagnosis
History and Symptoms
Patients who are being evaluated for torsades de pointes should be asked about a history of syncope, and family history of long QT syndrome, sudden cardiac death, or sudden infant death syndrome. Torsades de pointes is associated with a fall in blood pressure, which often gives rise to syncopal symptoms. The patient may experience nausea, shortness of breath, dizziness,chest pain, and possibly ventricular fibrillation and sudden cardiac death.
Physical Examination
The physical exam during or directly after an episode of torsade de pointes, may reveal pallor and diaphoresis, loss of consciousness, and bradycardia followed by tachycardia.
Laboratory Findings
Laborotory tests obtained in a person with torsade de pointes will vary depending on the most likely etiology for their arrhythmia. Cardiac enzymes and levels of potassium, magnesium and calcium should be obtained.
Electrocardiogram
The EKG is the main diagnostic tool for torsades de pointes. EKG will show that the QRS complexes seem to twist around the horizontal isoelectric axis. Polymorphic ventricular tachycardia is distinguished from torsades de pointes by the absence of prolongation of the QT segment.
The ECG below is the characteristic tracing showing the “twisting” (blue line) of Torsade de pointes

Treatment
An understanding of the pathophysiology has led to development of treatment modalities like pacing, isoproterenol and drugs like magnesium and beta blockers.If the episode of does not terminate on its own and degenerates into ventricular fibrillation, cardioversion is required.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The term “torsade de pointes” was first described by Dessertenne in 1966, based on the characteristic “twisting” pattern of ventricular tachycardia seen on EKG.
Historical Perspective
- It was first described by Dessertenne in 1966[1] and refers to a specific variety of ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram (ECG).
- The French term is largely due to the fact that the phenomenon was originally described in a French medical journal by Dessertenne in 1966, when he observed this rhythm disorder in an 80-year-old female patient with complete intermittent atrioventricular block.
- There has been much debate in the Circulation journal among French and American scientist whether one should write Torsades de Pointes or Torsade de Pointes.
- As for now Torsade is prefered (unless one sees rotations around more than one axis in one episode), but both forms are used in similar frequency.[2]
References
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.
Overview
Torsades de pointes is defined as the presence of polymorphic ventricular tachycardia with a prolonged QT segment on EKG. It is characterized by a constantly changing rhythm amplitude which comes from the ventricular depolarizing waves constantly shifting its axis. The underlying mechanism is thought to be triggered activity arising as a consequence of early after-depolarizations. During Torsade de pointes the ventricles depolarize in a circular fashion resulting in QRS complexes with a continuously turning heart axis around the baseline (hence the name Torsade de Pointes).
Pathophysiology
Torsade de pointes is characterized by constantly changing rhythm amplitude. ‘Torsade de pointes’ in French means “Twisting of the Points”. The changing rhythm amplitudes comes from the ventricular depolarizing waves constantly shifting its axis. It is usually caused by hypomagnesemia, hypokalemia, and malnourished alcoholics. Although Torsades de Pointes (TdP) is a rare ventricular arrhythmia, it can degenerate into ventricular fibrillation, leading to death without rapid medical intervention. TdP is associated with long QT syndrome, a condition whereby prolonged QT intervals are visible on the ECG.
Torsade de pointes is typically initiated by a short-long-short interval. A ventricular extrasystole (first beat: short) is followed by a compensatory pause. The following beat (second beat: long) has a longer QT interval. If the next beat follows shortly thereafter, there is a good chance that this third beat falls within the QT interval, resulting in the R on T phenomenon and subsequent Torsade de pointes. During Torsade de pointes the ventricles depolarize in a circular fashion resulting in QRS complexes with a continuously turning heart axis around the baseline (hence the name Torsade de Pointes).
Video: Torsade de pointes
{{#ev:youtube|1ccTO6fNobU}}
{{#ev:youtube|JDumoHHZocA}}
References
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Common causes for torsades de pointes include hypomagnesemia and hypokalemia. It is commonly seen in malnourished individuals and chronic alcoholics. Drug interactions such as erythromycin or Avelox, taken concomitantly with inhibitors like nitroimidazole, diarrhea, dietary supplements, and various medications like methadone, lithium, tricyclic antidepressants or phenothiazines may also contribute to causing torsades de pointes.
Causes
The List of Drugs that Cause Torsades de pointes
Drugs that are generally accepted to have a risk of causing torsades de pointes:
- Amiodarone
- Arsenic trioxide
- Astemizole
- Azithromycin
- Bepridil
- Chloroquine
- Chlorpromazine
- Cisapride
- Citalopram
- Clarithromycin
- Disopyramide
- Dofetilide
- Dolasetron mesylate
- Domperidone
- Droperidol
- Erythromycin
- Felbamate
- Halofantrine
- Haloperidol
- Clozapine
- Ibutilide
- Levomethadyl
- Mesoridazine
- Methadone
- Moxifloxacin
- Pentamidine
- Pimozide
- Probucol
- Procainamide
- Quinidine
- Sevoflurane
- Sotalol
- Sparfloxacin
- Terfenadine
- Thioridazine
- Toremifene
- Vandetanib
Drugs that Possibly Cause Torsades de pointes
Drugs that in some reports have been associated with torsades de pointes and/or QT prolongation but at this time lack substantial evidence for causing torsades de pointes.
- Alfuzosin
- Amantadine
- Artenimol and piperaquine
- Atazanavir
- Azithromycin
- Chloral hydrate
- Clozapine
- Dolasetron
- Dronedarone
- Eribulin
- Escitalopram
- Famotidine
- Felbamate
- Fingolimod
- Flecainide
- Foscarnet
- Fosphenytoin
- Gatifloxacin
- Gemifloxacin
- Granisetron
- Iloperidone
- Indapamide
- Isradipine
- Lapatanib
- Levofloxacin
- Lithium
- Mirtazipine
- Moexipril / HCTZ
- Moxifloxacin
- Nicardipine
- Nilotinib
- Octreotide
- Ofloxacin
- Ondansetron
- Oxytocin
- Paliperidone
- Perflutren
- Quetiapine
- Ranolazine
- Risperidone
- Roxithromycin
- Sertindole
- Sunitinib
- Tacrolimus
- Tamoxifen
- Telithromycin
- Tizanidine
- Vardenafil
- Venlafaxine
- vandetanib
- Voriconazole
- Ziprasidone
The List of Drugs that Cause Torsades de pointes in Certain Conditions
Drugs that, in some reports, have been weakly associated with torsades de pointes and/or QT prolongation but that are unlikely to be a risk for torsades de pointes when used in usual recommended dosages and in patients without other risk factors (e.g., concomitant QT prolonging drugs, bradycardia, electrolyte disturbances, congenital long QT syndrome, concomitant drugs that inhibit metabolism)
- Amisulpride
- Amitriptyline
- Amoxapine
- Ciprofloxacin
- Citalopram
- Clomipramine
- Desipramine
- Diphenhydramine
- Doxepin
- Fluconazole
- Fluoxetine
- Galantamine
- Imipramine
- Itraconazole
- Ketoconazole
- Mexiletine
- Nortriptyline
- Paroxetine
- Protriptyline
- Ritonavir
- Sertraline
- Solifenacin
- Trazodone
- Trimethoprim-Sulfamethoxazole
- Trimipramine
Sources
References
Differentiating Torsades de pointes from other Diseases
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Torsades de pointes should be differentiated from other conditions or disorders that may present in a similar way, such as other arrhythmias, drug toxicity, syncope and other cardiac conditions.
Differential Diagnosis
- Ventricular Tachycardia (polymorphic, monomorphic)
- Supraventricular tachycardia
- Ventricular Fibrillation
- Sudden Cardiac Death
- Syncope
- Renal Failure
- Complication dialysis
- Drug toxicity like antiarrhythmic, antihistaminics
The table below provides information on the differential diagnosis of torsades de pointes in terms of ECG appearance:
| Disease Name | Causes | ECG Characteristics | ECG view |
|---|---|---|---|
| Ventricular tachycardia [1][2][3][4][5] |
|
| |
| Ventricular fibrillation [7][8][9][10] |
|
| |
| Ventricular flutter [12][13][14] |
|
| |
| Asystole [16][17] |
|
| |
| Pulseless electrical activity [19][20] |
|
|
|
| Torsade de Pointes [22][23][24] |
|
|
References
- ↑ Ajijola, Olujimi A.; Tung, Roderick; Shivkumar, Kalyanam (2014). “Ventricular tachycardia in ischemic heart disease substrates”. Indian Heart Journal. 66: S24–S34. doi:10.1016/j.ihj.2013.12.039. ISSN 0019-4832.
- ↑ Meja Lopez, Eliany; Malhotra, Rohit (2019). “Ventricular Tachycardia in Structural Heart Disease”. Journal of Innovations in Cardiac Rhythm Management. 10 (8): 3762–3773. doi:10.19102/icrm.2019.100801. ISSN 2156-3977.
- ↑ Coughtrie, Abigail L; Behr, Elijah R; Layton, Deborah; Marshall, Vanessa; Camm, A John; Shakir, Saad A W (2017). “Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort”. BMJ Open. 7 (10): e016627. doi:10.1136/bmjopen-2017-016627. ISSN 2044-6055.
- ↑ El-Sherif, Nabil (2001). “Mechanism of Ventricular Arrhythmias in the Long QT Syndrome: On Hermeneutics”. Journal of Cardiovascular Electrophysiology. 12 (8): 973–976. doi:10.1046/j.1540-8167.2001.00973.x. ISSN 1045-3873.
- ↑ de Riva, Marta; Watanabe, Masaya; Zeppenfeld, Katja (2015). “Twelve-Lead ECG of Ventricular Tachycardia in Structural Heart Disease”. Circulation: Arrhythmia and Electrophysiology. 8 (4): 951–962. doi:10.1161/CIRCEP.115.002847. ISSN 1941-3149.
- ↑ ECG found in of https://en.ecgpedia.org/index.php?title=Main_Page
- ↑ Koplan BA, Stevenson WG (March 2009). “Ventricular tachycardia and sudden cardiac death”. Mayo Clin. Proc. 84 (3): 289–97. doi:10.1016/S0025-6196(11)61149-X. PMC 2664600. PMID 19252119.
- ↑ Maury P, Sacher F, Rollin A, Mondoly P, Duparc A, Zeppenfeld K, Hascoet S (May 2017). “Ventricular arrhythmias and sudden death in tetralogy of Fallot”. Arch Cardiovasc Dis. 110 (5): 354–362. doi:10.1016/j.acvd.2016.12.006. PMID 28222965.
- ↑ Saumarez RC, Camm AJ, Panagos A, Gill JS, Stewart JT, de Belder MA, Simpson IA, McKenna WJ (August 1992). “Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms”. Circulation. 86 (2): 467–74. doi:10.1161/01.cir.86.2.467. PMID 1638716.
- ↑ Bektas, Firat; Soyuncu, Secgin (2012). “Hypokalemia-induced Ventricular Fibrillation”. The Journal of Emergency Medicine. 42 (2): 184–185. doi:10.1016/j.jemermed.2010.05.079. ISSN 0736-4679.
- ↑ ECG found in https://en.ecgpedia.org/index.php?title=Main_Page
- ↑ Thies, Karl-Christian; Boos, Karin; Müller-Deile, Kai; Ohrdorf, Wolfgang; Beushausen, Thomas; Townsend, Peter (2000). “Ventricular flutter in a neonate—severe electrolyte imbalance caused by urinary tract infection in the presence of urinary tract malformation”. The Journal of Emergency Medicine. 18 (1): 47–50. doi:10.1016/S0736-4679(99)00161-4. ISSN 0736-4679.
- ↑ Koster, Rudolph W.; Wellens, Hein J.J. (1976). “Quinidine-induced ventricular flutter and fibrillation without digitalis therapy”. The American Journal of Cardiology. 38 (4): 519–523. doi:10.1016/0002-9149(76)90471-9. ISSN 0002-9149.
- ↑ Dhurandhar RW, Nademanee K, Goldman AM (1978). “Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases”. Heart Lung. 7 (5): 783–7. PMID 250503.
- ↑ ECG found in https://en.ecgpedia.org/index.php?title=Main_Page
- ↑ ACLS: Principles and Practice. p. 71-87. Dallas: American Heart Association, 2003. ISBN 0-87493-341-2.
- ↑ ACLS for Experienced Providers. p. 3-5. Dallas: American Heart Association, 2003. ISBN 0-87493-424-9.
- ↑ ECG found in https://en.ecgpedia.org/index.php?title=Main_Page
- ↑ “2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7.2: Management of Cardiac Arrest.” Circulation 2005; 112: IV-58 – IV-66.
- ↑ Foster B, Twelve Lead Electrocardiography, 2nd edition, 2007
- ↑ ECG found in wikimedia Commons
- ↑ Li M, Ramos LG (July 2017). “Drug-Induced QT Prolongation And Torsades de Pointes”. P T. 42 (7): 473–477. PMC 5481298. PMID 28674475.
- ↑ Sharain, Korosh; May, Adam M.; Gersh, Bernard J. (2015). “Chronic Alcoholism and the Danger of Profound Hypomagnesemia”. The American Journal of Medicine. 128 (12): e17–e18. doi:10.1016/j.amjmed.2015.06.051. ISSN 0002-9343.
- ↑ Khan IA (2001). “Twelve-lead electrocardiogram of torsades de pointes”. Tex Heart Inst J. 28 (1): 69. PMC 101137. PMID 11330748.
- ↑ ECG found in https://en.ecgpedia.org/index.php?title=Main_Page
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Long QT syndrome is a risk factor for developing torsades de pointes, and can either be inherited as congenital mutations of ion channels carrying the cardiac impulse/action potential, or acquired as a result of drugs that block these cardiac ion currents. Other risk factors include electrolyte abnormalities, heart failure, left ventricular hypertrophy, female gender or renal and liver failure. Being on certain medications also pose a risk for developing torsades de pointes.
Risk Factors
Factors that are associated with an increased tendency toward torsades de pointes include:
- Familial long QT syndrome
- Class IA antiarrhythmics
- Hypomagnesemia
- Hypokalemia
- Hypoxia
- Acidosis
- Heart failure
- Left ventricular hypertrophy
- Slow heart rate
- Female gender
- Baseline electrocardiographic abnormalities
- Renal failure or liver failure
Clinical Correlation
- Drugs: quinidine, PCA, norpace, amiodarone, phenothiazines, tricyclic antidepressants, pentamidine.
- with quinidine majority of the cases occur within one week of initiation, and with therapeutic levels
- Electrolyte imbalances: hypokalemia, hypomagnesemia, hypocalcemia
- CAD
- MVP
- Variant angina
- Myocarditis
- Subarachnoid hemorrhage
- Congenital QT prolongation
- Liquid protein diets
- Hypothyroidism
- because of bradycardia and a prolonged QT syndrome
- Organophosphate poisoning [1] [2]
References
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.
Overview
Although Torsades de Pointes (TdP) is a rare ventricular arrhythmia, it can degenerate into ventricular fibrillation, leading to death without rapid medical intervention. TdP is associated with long QT syndrome, a condition whereby prolonged QT intervals are visible on the ECG.
References
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | EKG Examples | Echocardiography | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Related Chapters
Related Chapters
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
